Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes.
Cortellini A, Leonetti A, Catino A, Pizzutillo P, Ricciuti B, De Giglio A, Chiari R, Bordi P, Santini D, Giusti R, De Tursi M, Brocco D, Zoratto F, Rastelli F, Citarella F, Russano M, Filetti M, Marchetti P, Berardi R, Torniai M, Cortinovis D, Sala E, Maggioni C, Follador A, Macerelli M, Nigro O, Tuzi A, Iacono D, Migliorino MR, Banna G, Porzio G, Cannita K, Ferrara MG, Bria E, Galetta D, Ficorella C, Tiseo M. Cortellini A, et al. Among authors: de giglio a, de tursi m. Clin Transl Oncol. 2020 Jun;22(6):844-851. doi: 10.1007/s12094-019-02193-w. Epub 2019 Aug 7. Clin Transl Oncol. 2020. PMID: 31392645
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.
Ficorella C, Ricevuto E, Morelli MF, Morese R, Cannita K, Cianci G, Porzio G, Di Rocco ZC, De Galitiis F, De Tursi M, Tinari N, Iacobelli S, Marchetti P. Ficorella C, et al. Among authors: de galitiis f, de tursi m. Oncol Rep. 2006 May;15(5):1345-50. doi: 10.3892/or.15.5.1345. Oncol Rep. 2006. PMID: 16596209 Clinical Trial.
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer.
Natoli C, Cianchetti E, Tinari N, Angelucci D, Grassadonia A, Zilli M, Ficorella C, Ricevuto E, Grossi S, De Tursi M, Carella C, Rispoli AI, Iacobelli S. Natoli C, et al. Among authors: de tursi m. Ann Oncol. 2007 Jun;18(6):1015-20. doi: 10.1093/annonc/mdm076. Epub 2007 Mar 17. Ann Oncol. 2007. PMID: 17369601 Free article. Clinical Trial.
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice.
Angelucci D, Tinari N, Grassadonia A, Cianchetti E, Ausili-Cefaro G, Iezzi L, Zilli M, Grossi S, Ursini LA, Scognamiglio MT, Castrilli G, De Tursi M, Noccioli P, Cioffi P, Iacobelli S, Natoli C. Angelucci D, et al. Among authors: de tursi m. J Cancer Res Clin Oncol. 2013 Feb;139(2):269-80. doi: 10.1007/s00432-012-1325-9. Epub 2012 Oct 10. J Cancer Res Clin Oncol. 2013. PMID: 23052698 Free PMC article.
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.
Natoli C, Vici P, Sperduti I, Grassadonia A, Bisagni G, Tinari N, Michelotti A, Zampa G, Gori S, Moscetti L, De Tursi M, Panebianco M, Mauri M, Ferrarini I, Pizzuti L, Ficorella C, Samaritani R, Mentuccia L, Iacobelli S, Gamucci T. Natoli C, et al. Among authors: de tursi m. J Cancer Res Clin Oncol. 2013 Jul;139(7):1229-40. doi: 10.1007/s00432-013-1436-y. Epub 2013 Apr 20. J Cancer Res Clin Oncol. 2013. PMID: 23604446 Free PMC article.
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.
Marchetti A, Palma JF, Felicioni L, De Pas TM, Chiari R, Del Grammastro M, Filice G, Ludovini V, Brandes AA, Chella A, Malorgio F, Guglielmi F, De Tursi M, Santoro A, Crinò L, Buttitta F. Marchetti A, et al. Among authors: de pas tm, de tursi m. J Thorac Oncol. 2015 Oct;10(10):1437-43. doi: 10.1097/JTO.0000000000000643. J Thorac Oncol. 2015. PMID: 26295376 Free article.
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.
Bronte G, Franchina T, Alù M, Sortino G, Celesia C, Passiglia F, Savio G, Laudani A, Russo A, Picone A, Rizzo S, De Tursi M, Gambale E, Bazan V, Natoli C, Blasi L, Adamo V, Russo A. Bronte G, et al. Among authors: de tursi m. Oncotarget. 2016 Jun 14;7(24):35803-35812. doi: 10.18632/oncotarget.8130. Oncotarget. 2016. PMID: 26993607 Free PMC article.
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice.
Cortellini A, Gambale E, Cannita K, Brocco D, Parisi A, Napoleoni L, Masedu F, Irtelli L, De Tursi M, Natoli C, Ficorella C. Cortellini A, et al. Among authors: de tursi m. Thorac Cancer. 2018 Feb;9(2):241-252. doi: 10.1111/1759-7714.12570. Epub 2017 Dec 7. Thorac Cancer. 2018. PMID: 29388383 Free PMC article.
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study.
Cortellini A, Bersanelli M, Buti S, Gambale E, Atzori F, Zoratto F, Parisi A, Brocco D, Pireddu A, Cannita K, Iacono D, Migliorino MR, Gamucci T, De Tursi M, Sidoni T, Tiseo M, Michiara M, Papa A, Angius G, Tomao S, Fargnoli MC, Natoli C, Ficorella C. Cortellini A, et al. Among authors: de tursi m. Immunotherapy. 2018 Jun;10(8):643-655. doi: 10.2217/imt-2017-0167. Epub 2018 Mar 22. Immunotherapy. 2018. PMID: 29562816
107 results